Bicycle Therapeutics (BCYC)
Bicycle Therapeutics Statistics
Share Statistics
Bicycle Therapeutics has 69.06M shares outstanding. The number of shares has increased by 82.19% in one year.
| Shares Outstanding | 69.06M |
| Shares Change (YoY) | 82.19% |
| Shares Change (QoQ) | 0.11% |
| Owned by Institutions (%) | 60.72% |
| Shares Floating | 61.3M |
| Failed to Deliver (FTD) Shares | 288 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 4.28M, so 6.2% of the outstanding shares have been sold short.
| Short Interest | 4.28M |
| Short % of Shares Out | 6.2% |
| Short % of Float | 6.52% |
| Short Ratio (days to cover) | 6.95 |
Valuation Ratios
The PE ratio is -48.21 and the forward PE ratio is -3.67. Bicycle Therapeutics's PEG ratio is 0.51.
| PE Ratio | -48.21 |
| Forward PE | -3.67 |
| PS Ratio | 231.02 |
| Forward PS | 1.1 |
| PB Ratio | 10.28 |
| P/FCF Ratio | -49.1 |
| PEG Ratio | 0.51 |
Enterprise Valuation
Bicycle Therapeutics has an Enterprise Value (EV) of 162.04M.
| EV / Earnings | -0.96 |
| EV / Sales | 4.59 |
| EV / EBITDA | -0.98 |
| EV / EBIT | -0.77 |
| EV / FCF | -0.98 |
Financial Position
The company has a current ratio of 13.81, with a Debt / Equity ratio of 0.01.
| Current Ratio | 13.81 |
| Quick Ratio | 13.81 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.5 |
| Cash Flow / Debt | -41.28 |
| Interest Coverage | -121.31 |
Financial Efficiency
Return on equity (ROE) is -0.21% and return on capital (ROIC) is -25.61%.
| Return on Equity (ROE) | -0.21% |
| Return on Assets (ROA) | -0.18% |
| Return on Capital (ROIC) | -25.61% |
| Revenue Per Employee | $115,655.74 |
| Profits Per Employee | $-554,200 |
| Employee Count | 305 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.76M |
| Effective Tax Rate | 0.03 |
Stock Price Statistics
The stock price has increased by -63.09% in the last 52 weeks. The beta is 1.12, so Bicycle Therapeutics's price volatility has been higher than the market average.
| Beta | 1.12 |
| 52-Week Price Change | -63.09% |
| 50-Day Moving Average | 11.46 |
| 200-Day Moving Average | 19.21 |
| Relative Strength Index (RSI) | 36.13 |
| Average Volume (20 Days) | 326.12K |
Income Statement
In the last 12 months, Bicycle Therapeutics had revenue of 35.27M and earned -169.03M in profits. Earnings per share was -0.29.
| Revenue | 35.27M |
| Gross Profit | 35.27M |
| Operating Income | -209.87M |
| Net Income | -169.03M |
| EBITDA | -164.89M |
| EBIT | -209.87M |
| Earnings Per Share (EPS) | -0.29 |
Balance Sheet
The company has 879.52M in cash and 3.99M in debt, giving a net cash position of 875.53M.
| Cash & Cash Equivalents | 879.52M |
| Total Debt | 3.99M |
| Net Cash | 875.53M |
| Retained Earnings | -680.79M |
| Total Assets | 956.87M |
| Working Capital | 861.38M |
Cash Flow
In the last 12 months, operating cash flow was -164.72M and capital expenditures -1.24M, giving a free cash flow of -165.96M.
| Operating Cash Flow | -164.72M |
| Capital Expenditures | -1.24M |
| Free Cash Flow | -165.96M |
| FCF Per Share | -0.29 |
Margins
Gross margin is 100%, with operating and profit margins of -594.96% and -479.18%.
| Gross Margin | 100% |
| Operating Margin | -594.96% |
| Pretax Margin | -492.69% |
| Profit Margin | -479.18% |
| EBITDA Margin | -467.45% |
| EBIT Margin | -594.96% |
| FCF Margin | -470.47% |
Dividends & Yields
BCYC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3.16% |
| FCF Yield | -26.15% |
Analyst Forecast
The average price target for BCYC is $28, which is 204.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $28 |
| Price Target Difference | 204.7% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 1.71 |
| Piotroski F-Score | 4 |